Elita DeFeo1, Johannes Kurth1,
Chin-Lee Wu, Shulin Wu, W. Scott McDougal2, Leo L. Cheng3
1Pathology, Massachusetts General
Hospital, Charlestown, MA, United States; 2Urology, Massachusetts
General Hospital; 3Radiology, Pathology, Massachusetts General
Hospital
Our 2005 publication on the investigations of human prostate cancer meabolomics led to two major conclusions that metabolomic profiles can differentiate tissue specimens with and without cancer glands, as well as patient pathological stages. However, this study only proposed the metabolomic structure from the analysis of a training cohort and did not evaluate another independent testing cohort. In this study we report our analysis of a testing cohort that was measured precisely following the exact experimental procedures that guided the 2005 study for the training cohort.